Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Inclusion Criteria: * According to the current diagnostic criteria, diagnosed as PCV patients * Conbercept is used for treatment, and the recommended treatment scheme is 3+PRN * Local and systemic anti-VEGF therapy was not used for at least three months before enrollment * The patient volunteers to take part in this observational study, and signs the informed consent * The patient can follow-up regularly (at least 4 times of follow-up in one year) Exclusion Criteria: * The patient has serious systemic disease, and the current clinical treatment is contraindicated * Local or systemic anti-VEGF therapy was used for less than three months before enrollment * Existence of diseases unsuitable to accept intravitreal Conbercept, including uncontrolled hypertension and diabetes, AIDS, malignant tumors, active hepatitis, severe renal failure, severe mental, nerve, cardiovascular, respiratory and immune diseases * During six months before screening, there were cardiovascular events such as stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure * Ocular contraindications, including active intraocular inflammation, infectious endophthalmitis, corneal ulcer, scleritis, uncontrolled glaucoma and so on * Patients who could not follow up regularly * Patients who refuse to sign the informed consent * Others